Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Regentys Extra-Cellular Matrix Hydrogel
- Development stage
- Preclinical
- Lead developer
- Generex Biotechnology
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies, Hydrogel Systems → Drug Delivery Systems, Stem Cell Therapies → Cell Therapies
- Administration
- Rectal
01
Overview
Regentys Extra-Cellular Matrix Hydrogel (ECMH) is a first-in-class, non-pharmacologic regenerative medicine therapy developed by Regentys Corporation (formerly Asana Medical) for the treatment of Ulcerative Colitis and other inflammatory bowel diseases. The product consists of a proprietary, porcine-derived small intestine submucosa (SIS) extracellular matrix (ECM). Administered rectally as a powder reconstituted with saline, it gels at body temperature to form a "liquid bio-bandage" that coats the mucosal lining of the gastrointestinal tract. Unlike traditional immunosuppressive therapies, ECMH functions as a bio-scaffold that protects damaged tissue from fecal waste and provides a structural framework to recruit endogenous stem cells, thereby promoting natural tissue healing and regeneration. The FDA has indicated that the product can be approved through the Office of Device Evaluation via a 510(k) de novo application.
- Brand names
- Regentys Extra-Cellular Matrix Hydrogel
- Other names
- porcine-derived small intestine submucosa extracellular matrixSIS-ECMliquid bio-bandagebio-scaffold bandage
Beyond the preview
Go deeper on Regentys Extra-Cellular Matrix Hydrogel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regentys Extra-Cellular Matrix Hydrogel.